ClearPoint Neuro, Inc. (CLPT)
- Previous Close
5.51 - Open
5.51 - Bid 5.44 x 100
- Ask 5.65 x 100
- Day's Range
5.43 - 5.63 - 52 Week Range
4.05 - 10.80 - Volume
34,566 - Avg. Volume
152,448 - Market Cap (intraday)
149.154M - Beta (5Y Monthly) 0.92
- PE Ratio (TTM)
-- - EPS (TTM)
-0.90 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.00
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
www.clearpointneuro.comRecent News: CLPT
Performance Overview: CLPT
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLPT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLPT
Valuation Measures
Market Cap
149.15M
Enterprise Value
139.95M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.66
Price/Book (mrq)
7.04
Enterprise Value/Revenue
5.84
Enterprise Value/EBITDA
-6.67
Financial Highlights
Profitability and Income Statement
Profit Margin
-92.21%
Return on Assets (ttm)
-28.59%
Return on Equity (ttm)
-76.09%
Revenue (ttm)
23.95M
Net Income Avi to Common (ttm)
-22.09M
Diluted EPS (ttm)
-0.90
Balance Sheet and Cash Flow
Total Cash (mrq)
23.14M
Total Debt/Equity (mrq)
65.84%
Levered Free Cash Flow (ttm)
-6.05M